MINI, ENRICO

MINI, ENRICO  

Scienze della Salute (DSS)  

Mostra records
Risultati 1 - 20 di 364 (tempo di esecuzione: 0.044 secondi).
Titolo Data di pubblicazione Autore(i) File
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 2019 Correale, P; Staropoli, N; Pastina, P; Giannicola, R; Botta, C; Francini, E; Ridolfi, L; Mini, E; Ciliberto, D; Agostino, R M; Strangio, A; Azzarello, D; Nardone, V; Falzea, A; Tassone, P; Giordano, A; Pirtoli, L; Francini, G; Tagliaferri, P S
2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial 2015 Taieb, J.; Zaanan, A.; Malicot, K. Le; Julie, C.; Blons, H.; Mineur, L.; Tabernero, J.; Mini, E.; Folprecht, G.; Laethem, J.L. Van; Lepage, C.; Emile, J.F.; Laurent-Puig, P.
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 2012 F. Guidi; M. Puglia; C. Gabbiani; I. Landini; T. Gamberi; D. Fregona; M.A. Cinellu; S. Nobili; E. Mini; L. Bini; P.A. Modesti; A. Modesti; L. Messori
6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial 2011 Correale, P.; Rotundo, M.S.; Botta, C.; Guglielmo, A.; Licchetta, A.; Conca, R.; Tassone, P.; Ridolfi, R.; Mini, E.; Tagliaferri, P.
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. 1995 A. Arcangeli; L. Bianchi; A. Becchetti; L. Faravelli; M. Coronnello; E. Mini; M. Olivotto; E. Wanke
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 2019 Lavacchi, Daniele; Mini, Enrico; Roviello, Giandomenico
Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19) 2021 Giorgione, Roberta; Santini, Daniele; Stellato, Marco; Basso, Umberto; Bimbatti, Davide; Palmieri, Valeria Emma; Doni, Laura; Antonuzzo, Lorenzo; Bersanelli, Melissa; Buti, Sebastiano; De Giorgi, Ugo; Galli, Luca; Sbrana, Andrea; Conca, Raffaele; Carella, Claudia; Naglieri, Emanuele; Mini, Enrico; Pignata, Sandro; Procopio, Giuseppe; Roviello, Giandomenico
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients 2017 Taieb, J; Balogoun, R; Le Malicot, K; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, Jl; Emile, Jf; Mulot, C; Fratté, S; Levaché, Cb; Saban-Roche, L; Thaler, J; Petersen, Ln; Bridgewater, J; Perkins, G; Lepage, C; Van Cutsem, E; Zaanan, A; Laurent-Puig, P
Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial 2016 Taieb, J.; Le Malicot, K.; Balogoum, R.; Tabernero, J.; Mini, E.; Folprecht, G.; van Laethem, J-L.; Emile, J-F.; Mulot, C.; Fratté, S.; Levaché, C-B.; Saban-Roche, L.; Thaler, J.; Petersen, L. Nørgård; Sanchez, E.; Bridgewater, J.; Perkins, G.; Lepage, C.; Zaanan, A.; Laurent-Puig, P.
Adjuvant FOLFOX4 +/- cetuximab in kras wildtype patients with resected stage III colon cancer results from the PETACC8 Intergroup Trial 2012 Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Sanches E; Nørgård Petersen L; Rougier P; Collette L; Praet M; Girault C; Schneider M; Squifflet P; Laurent-Puig P; Van Cutsem E; Bedenne L; Lepage C.
Adjuvant FOLFOX4 plus or minus cetuximab (cmab) in patients (pts) with kras mutant (mkras) resected stage III colon cancer (cc). Results from the PETACC8 Intergroup Trial 2012 Salazar R; Mini E; Folprecht G; Subtil F; van Laethem J; Thaler J; Bridgewater JA; Van Cutsem E; Lepage C; Taieb J
Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (pts) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC8 Intergroup Phase III Trial. 2012 Taieb J; Tabernero J; Mini E; Subtil f; Folprecht G; van Laethem JL; Thaler J; Bridgewater JA; van Cutsem E; Rougier P; Collette L; Praet M; Schneider M; Bouché O; Lepage C; Girault C; Emile JF; Laurent-Puig P.
Adjuvant therapy of colorectal carcinoma with 5-fluorouracil and l-folinic acid alone or combined with levamisole or interferon-alfa2a. Preliminary toxicological results of a multicenter study of the Italian Cooperative Oncological-Surgical Group (GOCCI) 1996 T. Mazzei; E. Mini; P. Mazzoni; F. Ficari; P. Periti; F. Tonelli; and other participants of the Gruppo Oncologico-Chirurgico Cooperativo Italiano (GOCCI)
Administering gemcitabine as fixed-dose-rate infusion in combination with cisplatin, potentially effective target plasma concentrations are achieved in patients with advanced non-small cell lung cancer 2007 Marangon E, Sala F, Caffo O, D'Incalci M, Galligioni E, Fallani S, Nobili S, Cassetta M, Mini E, Zucchetti M
ADVANCED COLORECTAL CANCER (ACRC) IN ELDERLY PATIENTS: EVALUATION OF THREE DIFFERENT OXALIPLATIN-BASED CHEMOTHERAPY REGIMENS - Session D: Colo-rectal Cancer 2005 Pinto C, Di Fabio F, Gentile AL, Mini E, Giaquinta S, Rojas Llimpe FL, Mutri V, Piana E, Mazzei T, Martoni A
Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study 2017 Nobili S, Mini, E, Mazzei T, Vannacci A
Adverse effects of macrolide antibacterials. 1993 P. Periti; T. Mazzei; E. Mini; A. Novelli
ALTERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy 2021 Spinelli, Sara; Mini, Enrico; Monteleone, Erminio; Angiolini, Catia; Roviello, Giandomenico
Aminoglucosidi 2005 A.Novelli; S.Fallani; E.Mini; T.Mazzei
AMINOGLUCOSIDI 2016 Novelli A, Fallani S, Mini E, Mazzei T